+1 650 419 9974 contact@chempartner.com
  • Careers
  • Contact Us
ChemPartner
  • About
    • About ChemPartner
    • CRO Services
    • CDMO Services
    • Awards & Accolades
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
      • ADC
      • PROTAC
      • Carbohydrate Chemistry
      • Nucleoside, Nucleotide, and Nucleic Acid Chemistry
    • Biology and Pharmacology
      • In Vitro Biology
      • Cell Biology
      • Oncology
      • Immunology and Inflammation
      • Immuno-oncology
      • Neuroscience
    • DMPK and Exploratory Toxicology
      • In Vitro ADME
      • Pharmacokinetics
      • Exploratory Toxicology
      • Bioanalysis
      • Regulatory Filing
      • Pathology Core Facility
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical, Biophysical Characterization, and Developability
      • B Cell Cloning
    • Biologics CMC
      • Developability Assessment
      • Cell Line Development and Banking
      • Manufacturing Process Development and Scale-up
      • Formulation Development
      • Extractables and Leachables
      • Pilot-Scale Production
      • cGMP Manufacturing
      • Analytical Development and Testing
  • News
    • Latest News
    • Events
  • Blog
  • Resources
    • Publications
    • Info Sheets
    • Webinars
Select Page
Impact Starts in the Lab: Using Preclinical Models to Combat Autoimmune & Autoinflammatory Arthritis

Impact Starts in the Lab: Using Preclinical Models to Combat Autoimmune & Autoinflammatory Arthritis

by Jenny Medina | May 20, 2025 | Blog, Drug Discovery/Drug Development

ChemPartner brings awareness about Autoimmune & Autoinflammatory Arthritis on 2025 AiArthritis Day Invisible and misunderstood: how it is to live with an autoimmune disease? “I think the hardest part of having an autoimmune disease is spending any free time I have...
From Mutation to Metastasis: Preclinical Assay Platform for KRAS G12C Targeted Therapy

From Mutation to Metastasis: Preclinical Assay Platform for KRAS G12C Targeted Therapy

by Jenny Medina | May 16, 2025 | Blog, Drug Discovery/Drug Development

Three-decade long saga brings promise and breakthrough for better therapies Kirsten rat sarcoma (KRAS) has been long recognized as the most commonly mutated protooncogene, and under active exploration in cancer research for the past 30 years. The target has been at...
  • Careers
  • Contact Us
©2023 Shanghai ChemPartner